Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > PFE to acquire Seagen?

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Feb 27, 2023 10:58am

76 Views

Post# 35307110

RE:RE:RE:RE:PFE to acquire Seagen?

What this rumor does is to set the stage with the market, and its future expectations, for Pfizer to make multiple M&A deals this year for an accumulated value of US$40 Billion or more, without experiencing any negative reaction to the company's M&A moves.

<< Previous

Bullboard Posts

Next >>

Rock Tech notches official permit for German lithium refinery